Entering text into the input field will update the search result below

IPO Update: Generation Bio Proposes IPO Terms


Quick Take

Generation Bio (NASDAQ:GBIO) intends to raise $126 million from the sale of its common stock in a U.S. IPO, per an amended registration statement.

The company is a pre clinical developer of genetic treatments for liver and retinal diseases.

GBIO is an ultra early stage biopharma and the IPO appears more suited to long-term oriented institutional venture investors rather than individuals.

Company & Technology

Cambridge, Massachusetts-based Gen Bio was founded to create a non-viral gene therapy pipeline to deliver genetic payloads for large or multiple genes to various tissues in liver and retinal diseases.

Management is headed by president and CEO Geoff McDonough, M.D., who has been with the firm since October 2017 and was previously president and CEO of Swedish Orphan Biovitrum AB, a biopharma firm.

Below is a brief overview video of phenylketonuria:

Source: Osmosis

All of the firm's candidates are still at a preclinical stage, with its PKU (phenylketonuria) and Hemophilia A programs the furthest along.

Below is the current status of the company’s drug development pipeline:

Source: Company S-1 Filing

Investors in the firm have invested at least $224 million and include Atlas Venture Fund, Fidelity Investments, T. Rowe Price and Invus.

Market & Competition

According to a 2019 market research report by Grand View Research, the market for phenylketonuria treatment was $446 million in 2018.

This represents a forecast CAGR (Compound Annual Growth Rate) of 11.0% from 2019 to 2026.

Key elements driving this expected growth are an increasing incidence of PKU worldwide as well as new pipeline drugs from biopharma firms, some of which have received FDA fast-track designation.

The North America region accounts for approximately 50% of worldwide treatment activity, with the European region expected to grow the fastest through 2026 due to the entry of the palynziq drug treatment and delay of

Gain Insight and actionable information on U.S. IPOs with IPO Edge research.

Members of IPO Edge get the latest IPO research, news, and industry analysis. Get started with a free trial!

This article was written by

Donovan Jones profile picture

Donovan Jones is a research specialist with 15 years of experience identifying opportunities for IPOs and software companies.

He also leads the investing group

IPO Edge

which offers: actionable information on growth stocks through first look S-1 filings, previews on upcoming IPOs, an IPO calendar for tracking what’s on the horizon, a database of U.S. IPOs, and a guide to IPO investing to walk you through the entire IPO lifecycle - from filing to listing to quiet period and lockup expiration dates.

Learn more


Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (6)

btw: rubius killed its PKU program about 6 months ago. would be nice to have up to date analysis!
looks like this one is going to the dumpster. Their main pitching points are - dsDNA larger than AAV ssDNA to deliver larger genes and cite directed LNPs. Although they showed expression with the DNA in animals, they do not show prof of concept with the ctLNPs which makes you wonder if this thing even works. sure LNPs work for MRNA and ALNY but here they intend to add paptides to the LNPs which make production process more difficult as these particles tend to aggregate. They should have shown this piece of data for the IPO, it would have been a blast.
IPO did fine, it helped they raised some much from venture cap, over $230 million, I see lots of potential for several big partners in several indications
And where does the information come from that there are peptides and not DNA molecules in the form of a plasmid?
Peptides on the vesicles - nano particle vehicle.
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About GBIO Stock

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on GBIO

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.